While Gaggini et al. and Shi et al. found no significant difference in serum irisin levels between 56 HCC patients and healthy controls [55,65], studies involving 262 patients reported substantially lower circulating irisin levels [66,67], suggesting a potential link between irisin suppression and disease severity (Table 3). This evidence concerns the gene FNDC5 and hepatocellular carcinoma.